SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 Prescriptions for

Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the third

Data related to fostamatinib accepted for oral presentation and two poster presentations SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that two-year safety and efficacy data from its FIT Phase 3 extension study (FIT3) for the